Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial

Controlled Trial ◽

Glucose Monitoring ◽

Glucose Sensing ◽

Blood Glucose Monitoring ◽

Open Label ◽

Randomized Controlled ◽

Sensing Technology

Effects of flash glucose-sensing technology-based continuous glucose monitoring on compliance of patients with type 2 diabetes mellitus: study protocol for a randomized controlled trial

Clinical Trials in Degenerative Diseases ◽

10.4103/2542-3975.254105 ◽

2019 ◽

Vol 4 (1) ◽

pp. 0

Author(s):

Jing Chen ◽

Na Luo ◽

Li Wang ◽

Zhen-Wen Zhang ◽

Yan Liu

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glucose Sensing ◽

Randomized Controlled ◽

Sensing Technology

Intervention of the Flash Glucose Sensing Technology on Glycemic Control and Treatment Satisfaction in Patients with Type 2 Diabetes Treated Intensively by Insulin—A Randomized Controlled Trial

Diabetes ◽

10.2337/db18-908-p ◽

2018 ◽

Vol 67 (Supplement 1) ◽

pp. 908-P ◽

Cited By ~ 1

Author(s):

MARIANNA YARON ◽

EYTAN ROITMAN ◽

GENYA AHARON-HANANEL ◽

ZOHAR LANDAU ◽

TALI GANZ ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Treatment Satisfaction ◽

Controlled Trial ◽

Glucose Sensing ◽

Randomized Controlled ◽

Sensing Technology

Effects of Sodium Glucose Co-Transporter 2 Inhibitor Canagliflozin in Patients with Type 2 Diabetes and Chronic Heart Failure (CANDLE): An Open-Label, Randomized Controlled Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3343659 ◽

2019 ◽

Author(s):

Atsushi Tanaka ◽

Itaru Hisauchi ◽

Isao Taguchi ◽

Akira Sezai ◽

Shigeru Toyoda ◽

...

Keyword(s):

Heart Failure ◽

Type 2 Diabetes ◽

Chronic Heart Failure ◽

Controlled Trial ◽

Open Label ◽

Randomized Controlled

RESVERATROL SUPPLEMENTATION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PROSPECTIVE, OPEN LABEL, RANDOMIZED CONTROLLED TRIAL

International Research Journal of Pharmacy ◽

10.7897/2230-8407.04849 ◽

2013 ◽

Vol 4 (8) ◽

pp. 245-249 ◽

Cited By ~ 20

Author(s):

Jayesh Kumar Bhatt ◽

Moola Joghee Nanjan

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Controlled Trial ◽

Open Label ◽

Randomized Controlled

Decision letter for "Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12‐week Randomized Controlled Trial"

10.1111/dom.13913/v3/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

Review for "Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12‐week Randomized Controlled Trial"

10.1111/dom.13913/v2/review3 ◽

2019 ◽

Author(s):

Tasuku Terada

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

Review for "Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12‐week Randomized Controlled Trial"

10.1111/dom.13913/v2/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

Review for "Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12‐week Randomized Controlled Trial"

10.1111/dom.13913/v1/review3 ◽

2019 ◽

Author(s):

Tasuku Terada

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

Review for "Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12‐week Randomized Controlled Trial"

10.1111/dom.13913/v1/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2018.03.035 ◽

2018 ◽

Vol 139 ◽

pp. 357-365 ◽

Cited By ~ 4

Author(s):

Andre Gustavo Daher Vianna ◽

Claudio Silva Lacerda ◽

Luciana Muniz Pechmann ◽

Michelle Garcia Polesel ◽

Emerson Cestari Marino ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Glucose Monitoring ◽

Glycemic Variability ◽

Modified Release ◽

Randomized Controlled ◽

And Control